Harvey Capital Management Inc. Invests $88,000 in Aquestive Therapeutics, Inc. (NASDAQ:AQST)

Harvey Capital Management Inc. acquired a new position in Aquestive Therapeutics, Inc. (NASDAQ:AQST) during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 17,600 shares of the company’s stock, valued at approximately $88,000.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Victory Capital Management Inc. bought a new position in shares of Aquestive Therapeutics in the 2nd quarter worth $27,000. nVerses Capital LLC purchased a new position in Aquestive Therapeutics in the third quarter worth $28,000. SG Americas Securities LLC bought a new position in Aquestive Therapeutics in the first quarter valued at $54,000. The Manufacturers Life Insurance Company purchased a new stake in Aquestive Therapeutics during the second quarter valued at about $76,000. Finally, Financial Advocates Investment Management lifted its stake in Aquestive Therapeutics by 70.0% during the second quarter. Financial Advocates Investment Management now owns 34,000 shares of the company’s stock worth $88,000 after purchasing an additional 14,000 shares during the last quarter. 32.45% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on AQST shares. HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of Aquestive Therapeutics in a report on Friday, October 25th. Leerink Partners boosted their price objective on shares of Aquestive Therapeutics from $12.00 to $13.00 and gave the stock an “outperform” rating in a report on Friday, October 25th. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $9.00 target price on shares of Aquestive Therapeutics in a report on Tuesday, October 8th. Six research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $8.83.

Aquestive Therapeutics Trading Up 0.5 %

Shares of NASDAQ:AQST traded up $0.03 during trading on Friday, reaching $5.52. 1,317,549 shares of the company traded hands, compared to its average volume of 1,744,926. Aquestive Therapeutics, Inc. has a 52-week low of $1.41 and a 52-week high of $6.23. The firm has a market capitalization of $502.65 million, a price-to-earnings ratio of -15.77 and a beta of 2.85. The business’s fifty day moving average is $4.88 and its 200-day moving average is $3.81.

Aquestive Therapeutics (NASDAQ:AQST) last announced its quarterly earnings results on Tuesday, August 6th. The company reported ($0.03) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.08. The firm had revenue of $20.10 million during the quarter, compared to the consensus estimate of $12.62 million. During the same period last year, the business earned ($0.10) EPS. On average, sell-side analysts predict that Aquestive Therapeutics, Inc. will post -0.48 earnings per share for the current fiscal year.

Aquestive Therapeutics Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.